Abstract

BackgroundGlaucomatous optic neuropathy (GON) is an anatomofunctional impairment of the optic nerve triggered by glaucoma. Recently, growth factors (GFs) have been shown to produce retinal neuroenhancement. The suprachoroidal autograft of mesenchymal stem cells (MSCs) by the Limoli retinal restoration technique (LRRT) has proven to achieve retinal neuroenhancement by producing GF directly into the choroidal space. This retrospectively registered clinical study investigated the visual function changes in patients with GON treated with LRRT.MethodsTwenty-five patients (35 eyes) with GON in progressive disease conditions were included in the study. Each patient underwent a comprehensive ocular examination, including the analysis of best corrected visual acuity (BCVA) for far and near visus, sensitivity by Maia microperimetry, and the study of the spectral domain-optical coherence tomography (SD-OCT). The patients were divided into two groups: a control group, consisting of 21 eyes (average age 72.2 years, range 50–83), and an LRRT group, consisting of 14 eyes (average age 67.4, range 50–84).ResultsAfter 6 months, the BCVA, close-up visus, and microperimetric sensitivity significantly improved in the LRRT-treated group (p<0.05), whereas the mean increases were not statistically significant in controls (p>0.5).ConclusionsPatients with GON treated with LRRT showed a significant increase in visual performance (VP) both in BCVA and sensitivity and an improvement of residual close-up visus, in the comparison between the LRRT results and the control group. Further studies will be needed to establish the actual significance of the reported findings.

Highlights

  • Glaucomatous optic neuropathy (GON) is an anatomofunctional impairment of the optic nerve triggered by glaucoma

  • This study aimed to evaluate both the efficacy and safety of Limoli retinal restoration technique (LRRT) suprachoroidal Mesenchymal stem cell (MSC) graft in patients with GON

  • Patient characteristics A total of 35 eyes from 25 patients affected by GON (10 females and 15 males; mean age 70.7 ± 9.9 years, range 50–84 years) met the inclusion criteria and were enrolled in the study

Read more

Summary

Introduction

Glaucomatous optic neuropathy (GON) is an anatomofunctional impairment of the optic nerve triggered by glaucoma. The suprachoroidal autograft of mesenchymal stem cells (MSCs) by the Limoli retinal restoration technique (LRRT) has proven to achieve retinal neuroenhancement by producing GF directly into the choroidal space. This retrospectively registered clinical study investigated the visual function changes in patients with GON treated with LRRT. Glaucoma causes retinal ganglion cell (RGC) layer degeneration, impairing visual function. Limoli et al Stem Cell Research & Therapy (2021) 12:275 thinning of the neuroretinal rim and pathological cupping have been observed, resulting in specific nervous fiber damage corresponding to visual field defects. Hypotensive therapies, together with neurotrophic supplements, represent the recommended treatment for patients with GON to stop or slow down neurodegeneration

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call